The Effect of Next-Generation TKI in Non-Small Cell Lung Cancer after Failure of First-Line Treatment: a Meta-Analysis

Zhang, Lei; Ren, Hongwei; Wu, Qilong; Wu, Yanjuan; Song, Xiang

doi:10.1007/s12253-019-00669-2

Cited by 2 publications

(1 citation statement)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…suggested that adjusting drug doses or symptomatic supportive treatment could manage mild to moderate AEs (grade <3). Although next‐generation TKIs are considered to have potential value in reducing the incidence of AEs owing to their high affinity, 13 recent studies have demonstrated that next‐generation TKIs do not have an absolute advantage in treating AEs 137,138 …”

Section: Challenges Of Ros1‐targeted Therapymentioning

confidence: 99%

Current treatment and novel insights regarding ROS1‐targeted therapy in malignant tumors

Li,

Zhang,

Chen

et al. 2024

Cancer Medicine

View full text Add to dashboard Cite

BackgroundThe proto‐oncogene ROS1 encodes an intrinsic type I membrane protein of the tyrosine kinase/insulin receptor family. ROS1 facilitates the progression of various malignancies via self‐mutations or rearrangements. Studies on ROS1‐directed tyrosine kinase inhibitors have been conducted, and some have been approved by the FDA for clinical use. However, the adverse effects and mechanisms of resistance associated with ROS1 inhibitors remain unknown. In addition, next‐generation ROS1 inhibitors, which have the advantage of treating central nervous system metastases and alleviating endogenous drug resistance, are still in the clinical trial stage.MethodIn this study, we searched relevant articles reporting the mechanism and clinical application of ROS1 in recent years; systematically reviewed the biological mechanisms, diagnostic methods, and research progress on ROS1 inhibitors; and provided perspectives for the future of ROS1‐targeted therapy.ResultsROS1 is most expressed in malignant tumours. Only a few ROS1 kinase inhibitors are currently approved for use in NSCLC, the efficacy of other TKIs for NSCLC and other malignancies has not been ascertained. There is no effective standard treatment for adverse events or resistance to ROS1‐targeted therapy. Next‐generation TKIs appear capable of overcoming resistance and delaying central nervous system metastasis, but with a greater incidence of adverse effects.ConclusionsFurther research on next‐generation TKIs regarding the localization of ROS1 and its fusion partners, binding sites for targeted drugs, and coadministration with other drugs is required. The correlation between TKIs and chemotherapy or immunotherapy in clinical practice requires further study.

show abstract

Section: Challenges Of Ros1‐targeted Therapymentioning

confidence: 99%